This lipopolysaccharide and/or lipid A binder can be used as, for example, an agent for neutralizing a lipopolysaccharide and/or lipid A or an agent for removing a lipopolysaccharide and/or lipid A.
The lipopolysaccharide- and/or lipid A-binder may be used as, for example, a lipopolysaccharide- and/or lipid A-neutralizing agent or a lipopolysaccharide- and/or lipid A-scavenger.
A lipopolysaccharide moiety comprising a conserved triheptosylinner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extensions.
The anti-LPS antibody included may be specific for the O-specific chain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognises the core glycolipid of lipopolysaccharide.
Materials and methods for the selective removal of lipopolysaccharide during the purification of molecules of biopharmaceutical interest are based on a polymeric substrate that binds lipopolysaccharide.
Further provided are methods and compositions for extracting a lipopolysaccharide from a solution containing a polynucleotide.
The composition preferably comprises an antigen and a lipopolysaccharide in an oil-in-water formulation.
The polypeptide exhibits strong affinity for lipopolysaccharide, and is useful for removing endotoxin and as a therapeutic agent of bacterial infections.
The volume of an intracranial glioma tumor is decreased by contacting the tumor with both LPS and IFNϜ.
This cytokine microarray was used to measure secretion from human Dendritic cells (DCs) induced by lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-α).
RIP2 knockout mice are more resistant to endotoxic shock after challenge with bacterial lipopolysaccharide (LPS), which signals through TLR4.